Vanguard Group Inc Castle Biosciences Inc Transaction History
Vanguard Group Inc
- $5.12 Trillion
- Q2 2024
A detailed history of Vanguard Group Inc transactions in Castle Biosciences Inc stock. As of the latest transaction made, Vanguard Group Inc holds 1,577,514 shares of CSTL stock, worth $53.3 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,577,514
Previous 1,494,176
5.58%
Holding current value
$53.3 Million
Previous $33.1 Million
3.77%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding CSTL
# of Institutions
173Shares Held
25.5MCall Options Held
511KPut Options Held
130K-
Black Rock Inc. New York, NY3.04MShares$103 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT2.33MShares$78.6 Million0.27% of portfolio
-
Principal Financial Group Inc Des Moines, IA1.5MShares$50.6 Million0.02% of portfolio
-
Bellevue Group Ag Kuesnacht, V81.22MShares$41.1 Million0.44% of portfolio
-
Portolan Capital Management, LLC Boston, MA1.21MShares$40.9 Million2.33% of portfolio
About CASTLE BIOSCIENCES INC
- Ticker CSTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 26,297,000
- Market Cap $888M
- Description
- Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...